Gilead appoints Dietmar Berger as Chief Medical Officer effective Jan 2, 2025

GILEAD SCIENCES, INC.

Dietmar Berger, MD PhD, will become Chief Medical Officer and member of senior leadership team on January 2, 2025.
Berger succeeds Merdad Parsey, MD PhD, who will stay as Senior Advisor through Q1 2025.
Berger previously served as Chief Medical Officer and Global Head of Development at Sanofi.
Berger will oversee Gilead's virology, oncology, inflammation portfolio and global Development/Medical Affairs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.